Brief Article
Copyright ©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Oct 7, 2013; 19(37): 6278-6283
Published online Oct 7, 2013. doi: 10.3748/wjg.v19.i37.6278
Figure 1
Figure 1 Flow chart of patient conditions following treatment with de novo lamivudine and adefovir dipivoxil combination therapy and entecavir monotherapy for 96 wk. LAM: Lamivudine; ADV: Adefovir dipivoxil; ETV: Entecavir.